Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism.

The Journal of pharmacology and experimental therapeutics - 1 Feb 1994

Mikus G, Bochner F, Eichelbaum M, Horak P, Somogyi A A, Spector S

Abstract excerpt

Codeine and morphine are endogenous substances. Following administration of exogenous codeine the biotransformation to morphine is catalyzed by CYP2D6, which exhibits a genetic so-called debrisoquine/sparteine polymorphism which is expressed in two phenotypes, the extensive and poor metaboliser phenotypes. Poor metabolisers form only trace amounts of morphine. If endogenous morphine is biosynthesised in humans...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2D6
Share to Cytochrome P-450 Enzyme System

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mixed Function Oxygenases

Share to Morphine

Share to Phenotype

Share to Polymorphism, Genetic

Share to Quinidine

Source

Identifiers

PMID: 8113966

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism.PMID 8113966Read ↗

Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans.Semantic proximity Read ↗

The pharmacogenetics of codeine hypoalgesia.Semantic proximity Read ↗

Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.Semantic proximity Read ↗

Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers?Semantic proximity Read ↗

On the assessment of drug metabolism by assays of codeine and its main metabolites.Semantic proximity Read ↗

The impact of CYP2D6 polymorphisms on the pharmacokinetics of codeine and its metabolites in Mongolian Chinese subjects.Semantic proximity Read ↗

CYP2D6 phenotype-specific codeine population pharmacokinetics.Semantic proximity Read ↗

Influence of Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 (CYP2D6) Polymorphisms on Pain Sensitivity and Clinical Response to Weak Opioid AnalgesicsSemantic proximity Read ↗

Urinary excretion of codeine, ethylmorphine, and their metabolites: relation to the CYP2D6 activity.Semantic proximity Read ↗

Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.Semantic proximity Read ↗

Codeine O-demethylation: rat strain differences and the effects of inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.